Therefore, this study aimed to evaluate the efficacy and safety of regorafenib in patients with bevacizumab-refractory glioblastoma in a real-life setting and to investigate the potential benefits of continuous VEGFR inhibition. This evidence concerns the gene KDR and glioblastoma.